Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PYQUVI safely and effectively. See full prescribing information for PYQUVI. PYQUVI TM (deflazacort) oral suspension Initial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
PYQUVI is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.
- generic_name
- deflazacort
- product_names
- deflazacort
- ndc
- 73289-0089, 73289-0089-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en